Αρχική World News Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive... World News Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC Από Ogkologos - 14 Ιουλίου, 2026 228 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... 7 Νοεμβρίου, 2024 Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... 2 Ιουλίου, 2025 Cancer in My Community: Expanding Access to Genetic Testing in Mexico 1 Σεπτεμβρίου, 2020 Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... 21 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Health inequalities: breaking down barriers to cancer screening Lucky 13-A Male Breast Cancer Story Is there a future without Pap testing? Survival According Circulating Tumour DNA Status in the Study of Adjuvant...